If you did some research you would see that RAC is fully funded through to close to the end of the decade from existing shareholder support ($1.25 piggyback options) and the Australian tax payers (i.e. R&D tax rebate).
I have always been of the belief that if you treat your shareholders with respect and look after their interest that they will support the company. While some biotechs treat their retail shareholders as dumb farm animals, Race is not one of these.
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-110
-
- There are more pages in this discussion • 282 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
